ImmunityBio, Inc. (IBRX) Stock: Rebounds as UAE Approves ANKTIVA for Bladder and Lung Cancer
TLDR
- ImmunityBio stock rebounds as UAE grants ANKTIVA its broadest approval to date
- UAE clears ANKTIVA for bladder cancer across the full disease spectrum in adults
- ANKTIVA gains UAE approval for metastatic lung cancer after therapy failure
- Bladder cancer trial reports a 71% complete response rate with ANKTIVA in patients
- ImmunityBio expands ANKTIVA’s global regulatory reach across 34 countries worldwide
ImmunityBio (IBRX) shares gained 5.86% in pre-market trading to $7.23 after closing 2.01% lower at $6.83. The rebound followed UAE authorization for ANKTIVA across bladder and lung cancer indications with limited treatment options. The decision gives ImmunityBio its broadest regulatory approval while expanding the therapy’s international commercial reach.
UAE Expands ANKTIVA Approval Across Two Cancer Indications
The Emirates Drug Establishment approved ANKTIVA with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer. The authorization includes carcinoma in situ, mixed tumors, and papillary-only disease without carcinoma in situ. This marks the first approval covering the full BCG-unresponsive NMIBC spectrum under one regulatory decision.
… Continue reading the full article at the original source below.
